Search Result

Results for "

human LOXL2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Cytochrome P450 (1) Lysyl Oxidase (2) Monoamine Oxidase (4) Small Interfering RNA (siRNA) (1)
By Research Areas:	Cardiovascular Disease (3) Inflammation/Immunology (3) Metabolic Disease (1)
Oligonucleotides:	Human Pre-designed siRNA Sets (1) siRNAs (1)

Inhibitors & Agonists

Inhibitory Antibodies

Recombinant Proteins

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-114286A

PXS-5153A monohydrochloride 1 Publications Verification	Monoamine Oxidase	Inflammation/Immunology
PXS-5153A monohydrochloride is a potent, selective, orally active and fast-acting lysyl oxidase like 2/3 enzymatic *(LOXL2/LOXL3)* inhibitor, with an IC₅₀ of <40 nM for LOXL2 across all mammalian species and an IC₅₀ of 63 nM for human LOXL3. PXS-5153A monohydrochloride could reduce crosslinks and ameliorates fibrosis.

HY-P99047

Simtuzumab AB 0024; GS 6624	Monoamine Oxidase	Cardiovascular Disease Inflammation/Immunology
Simtuzumab (AB 0024; GS 6624) is a monoclonal antibody directed against Lysyl oxidase like-2 (LOXL2). Simtuzumab non-competitively blocks collagen cross-linking, reduces LOXL2 protein expression and attenuates extracellular matrix changes. Simtuzumab reduces myocardial fibrosis and prevents cardiac dysfunction. Simtuzumab lowers Myh7 and Nppa gene expression, reduces contraction heterogeneity, and cuts COL1A1 deposition. Simtuzumab can be used for the research of LMNA mutation-induced dilated cardiomyopathy, idiopathic pulmonary fibrosis, and primary sclerosing cholangitis .

HY-114286

PXS-5153A	Monoamine Oxidase	Inflammation/Immunology
PXS-5153A is a potent, selective, orally active and fast-acting lysyl oxidase like 2/3 enzymatic *(LOXL2/LOXL3)* inhibitor, with an IC₅₀ of <40 nM for LOXL2 across all mammalian species and an IC₅₀ of 63 nM for human LOXL3. PXS-5153A could reduce crosslinks and ameliorates fibrosis.

HY-151498A

PXS-4787 hydrochloride	Monoamine Oxidase	Others
PXS-4787 hydrochloride is a specific and effective pan-LOX (lysyl oxidase) inhibitor for abolishing lysyl oxidase activity. PXS-4787 hydrochloride inhibits LOX with IC₅₀s of 2 μM (Bovine LOX), 3.2 μM (rh LOXL1), 0.6 μM (rh LOXL2), 1.4 μM (rh LOXL3), 0.2 μM (rh LOXL4), respectively. PXS-4787 hydrochloride reduces deposition and crosslinking of collagen I secreted by human fibroblasts .

HY-170538

SNT-5382	Lysyl Oxidase Cytochrome P450	Cardiovascular Disease Metabolic Disease
SNT-5382 is a lysyl oxidase family (LOX) inhibitor and anti-fibrotic agent. SNT-5382 binds to the LTQ cofactor of LOXL2 and inhibits the enzymatic activities of LOXL3, LOXL4, LOXL1, CYP2C9, and CYP2C19. SNT-5382 reduces cardiac and liver fibrosis as well as collagen crosslinks, and improves cardiac function. SNT-5382 can be used for the research of heart failure, myocardial infarction, and nonalcoholic steatohepatitis-related liver fibrosis .

HY-RS07742

LOXL2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
LOXL2 Human Pre-designed siRNA Set A contains three designed siRNAs for LOXL2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LOXL2 Human Pre-designed siRNA Set A LOXL2 Human Pre-designed siRNA Set A

HY-183644

LNO 9	Lysyl Oxidase	Cardiovascular Disease
LNO 9 is an orally active *LOXL2* inhibitor and NO donor, with an IC₅₀ of 0.17 μM against human *LOXL2. LNO 9 competitively binds to the LTQ cofactor of LOXL2* to form an irreversible complex, thereby inhibiting collagen oxidation and abnormal cross-linking. LNO 9 releases nitric oxide (NO) to increase cGMP levels in pulmonary artery smooth muscle cells. LNO 9 inhibits hypoxia-induced collagen modification and possesses vasodilatory activity. LNO 9 ameliorates right ventricular hypertrophy and pulmonary artery medial thickness in rat models induced by hypoxia and Monocrotaline (HY-N0750), and can be used for research on pulmonary hypertension .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99047

Simtuzumab AB 0024; GS 6624	Monoamine Oxidase	Cardiovascular Disease Inflammation/Immunology
Simtuzumab (AB 0024; GS 6624) is a monoclonal antibody directed against Lysyl oxidase like-2 (LOXL2). Simtuzumab non-competitively blocks collagen cross-linking, reduces LOXL2 protein expression and attenuates extracellular matrix changes. Simtuzumab reduces myocardial fibrosis and prevents cardiac dysfunction. Simtuzumab lowers Myh7 and Nppa gene expression, reduces contraction heterogeneity, and cuts COL1A1 deposition. Simtuzumab can be used for the research of LMNA mutation-induced dilated cardiomyopathy, idiopathic pulmonary fibrosis, and primary sclerosing cholangitis .

Species:	Human (3)
Tag:	His (3)
Source:	HEK293 (2) CHO (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P74771

	LOXL2 Protein, Human (CHO, His) Lysyl oxidase homolog 2; Lysyl oxidase-related protein WS9-14; LOXL2	Human	CHO
	LOXL2 protein mediates post-translational oxidative deamination of lysine residues, leading to the formation of allysine. It specifically deaminates H3K4me3, inhibits TFIID-dependent transcription, represses E-cadherin, activates the IRE1-XBP1 pathway, and promotes cross-linking of extracellular matrix proteins. LOXL2 is involved in EMT, tumor progression, angiogenesis regulation, and chondrocyte differentiation. LOXL2 Protein, Human (CHO, His) is the recombinant human-derived LOXL2 protein, expressed by CHO , with C-His labeled tag.

HY-P74770

	LOXL2 Protein, Human (HEK293, His) Lysyl oxidase homolog 2; Lysyl oxidase-related protein WS9-14; LOXL2	Human	HEK293
	LOXL2 protein mediates post-translational oxidative deamination of lysine residues, leading to the formation of allysine. It specifically deaminates H3K4me3, inhibits TFIID-dependent transcription, represses E-cadherin, activates the IRE1-XBP1 pathway, and promotes cross-linking of extracellular matrix proteins. LOXL2 is involved in EMT, tumor progression, angiogenesis regulation, and chondrocyte differentiation. LOXL2 Protein, Human (HEK293, His) is the recombinant human-derived LOXL2 protein, expressed by HEK293 , with C-His labeled tag.

HY-P74770Y

	LOXL2 Protein, Human (HEK293, His, solution) Lysyl oxidase homolog 2; Lysyl oxidase-related protein WS9-14; LOXL2	Human	HEK293
	The LOXL2 protein functions as a mediator in the post-translational oxidative deamination of lysine residues on target proteins, leading to the formation of deaminated lysine (allysine). Acting as a transcription corepressor, LOXL2 specifically mediates deamination of trimethylated 'Lys-4' of histone H3 (H3K4me3), a specific tag for epigenetic transcriptional activation. Notably, LOXL2 does not exhibit activity against histone H3 when it is trimethylated on 'Lys-9' (H3K9me3) or 'Lys-27' (H3K27me3) or when 'Lys-4' is monomethylated (H3K4me1) or dimethylated (H3K4me2). Additionally, LOXL2 mediates deamination of methylated TAF10, a member of the transcription factor IID (TFIID) complex, inducing the release of TAF10 from promoters and leading to the inhibition of TFIID-dependent transcription. This repression results in the downregulation of genes essential for embryonic stem cell pluripotency, including POU5F1/OCT4, NANOG, KLF4, and SOX2. LOXL2 is involved in epithelial to mesenchymal transition (EMT), participating in the repression of E-cadherin (CDH1) through the deamination of histone H3. It interacts with the endoplasmic reticulum protein HSPA5, activating the IRE1-XBP1 pathway of the unfolded protein response, and is implicated in E-cadherin repression following hypoxia, potentially contributing to tumor progression. Furthermore, when secreted into the extracellular matrix, LOXL2 promotes the cross-linking of extracellular matrix proteins by mediating oxidative deamination of peptidyl lysine residues in precursors to fibrous collagen and elastin. It also acts as a regulator of sprouting angiogenesis and chondrocyte differentiation.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

LOXL2 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
LOXL2 Human Pre-designed siRNA Set A contains three designed siRNAs for LOXL2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.